AZN vs BBNX: fair value comparison
AstraZeneca PLC and Beta Bionics, Inc. · Updated 2026-10-19
BBNX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AZN currently ranks higher by quality score.
| AZN | BBNX | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $165.41 | $16.35 |
| 12-month range | $155.62–$209.48 | $8.86–$31.99 |
| Rank by discount to fair value | #1 of 108 Healthcare | — |
| Rank by quality score | #95 of 301 Healthcare | #96 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: AZN fair value analysis · BBNX fair value analysis